Registration - In-house Corporation

Novartis Pharmaceuticals Canada Inc. / Mark Vineis, Country President

Registration Information

In-house Corporation name: Novartis Pharmaceuticals Canada Inc.
Responsible Officer Name: Mark Vineis, Country President
Responsible Officer Change History
Initial registration start date: 2007-07-13
Registration status: Active
Registration Number: 957165-15599

Associated Communications

Total Number of Communication Reports: 94

Monthly communication reports in the last 6 months: 3

Version 37 of 39 (2024-01-01 to 2024-05-01)

Registration versions:

Version 37 of 39 (2024-01-01 to 2024-05-01)

Lobbying Information

Subject Matters

Health
Industry
Intellectual Property
International Trade
Justice and Law Enforcement
Research and Development
Science and Technology

Subject Matter Details

Policies or Program

Canadian Agency for Drugs and Technologies in Health (CADTH), including Therapeutic Reviews and the Common Drug Review as it relates to reimbursement recommendations for decision-making process and framework.
Federal Innovation agenda. Working with our Industry Associations (Innovative Medicines Canada and BIOTECanada) to ensure that innovative medicines, and our contribution to Research and Development in Canada are part of the consultation process in the development of this new innovation agenda.
Federal Public Drug Plans, with respect to the reimbursement of drug products for the Federal plan beneficiaries
Science and Technology Strategy, advocating for the development of a Biopharma sector in support of more research & development in Canada.
Working with our Industry Associations (Innovative Medicines Canada and BIOTECanada) to provide industry recommendations on Canada's Biomanufacturing and Life Sciences Strategy, National Pharmacare, Intellectual property as well as pricing reforms (PMPRB)

Policies or Program, Regulation

R&D requirements set forth through the Patent Medicines Pricing Review Board (PMPRB)

Regulation

Patent Medicines Pricing Review Board reforms, regarding both the revised regulations and draft guidelines
Patented Medicine Prices Review Board (PMPRB) Regulations as related to reporting requirements and pricing guidelines.
Patented Medicines (Notice of Compliance) Regulations as it relates to regulation of intellectual property for therapeutic products. Novartis is working with our industry associations (Innovative Medicines Canada and BIOTECanada) to provide a written response to Guideline consultation process and will provide our own corporate submission.

Communication Techniques

Written communication
Oral communication

Government Institutions

Atlantic Canada Opportunities Agency (ACOA)
Canadian Heritage (PCH)
Finance Canada (FIN)
Global Affairs Canada (GAC)
Health Canada (HC)
House of Commons
Indigenous Services Canada (ISC)
Innovation, Science and Economic Development Canada (ISED)
Natural Resources Canada (NRCan)
Pacific Economic Development Canada (PacifiCan)
Patented Medicine Prices Review Board (PMPRB)
Prime Minister's Office (PMO)
Treasury Board Of Canada Secretariat (TBS)
Veterans Affairs Canada (VAC)

In-house Corporation Details

Description of activities

Marketing & distribution of pharmaceuticals products.

Responsible officer name and position during the period of this registration

Mark Vineis, Country President

Government funding

No government funding was received during the last completed financial year.

In-house Corporation Contact Information

Address:
700 St-Hubert St., Suite 100
Montreal, QC H2Y 0C1
Canada

Telephone number: 514-631-6775

Parent Company Information

Novartis Holding AG
- Forum 1
  Novartis Campus
  Basel CH-4056
  Switzerland

Subsidiary Beneficiary Information

Novartis Pharmaceuticals Canada Inc. does not have any subsidiaries that could have a direct interest in the outcome of the undertaking

Lobbyists Details

Senior Officers whose lobbying activities represent less than 20% of their Duties

Mark Vineis, Country President | No public offices held

Senior Officers and Employees whose lobbying activities represent 20% or more of their Duties

Shona Kinley, Director, Public Affairs and Government Relations (Fed-Atlantic) | Public offices held

Novartis Pharmaceuticals Canada Inc.

The following names have been used on or after July 2, 2008

Name	From	To
Novartis Pharmaceuticals Canada Inc.	2010-01-04	current

The following names have been used before July 2, 2008

Novartis Pharmaceuticals Canada Inc.

Novartis Pharmaceuticals Canada Inc.

Responsible Officer History
Responsible Officer Name	From (YYYY-MM-DD)	To (YYYY-MM-DD)
Mark Vineis	2024-01-01	Current
Pedro Ferreira	2023-10-01	2024-01-01
Andrea Marazzi	2022-06-01	2023-10-01
Christian Macher	2019-05-01	2022-06-01
Thea Discepola	2019-03-01	2019-05-01
Janice Murray	2017-05-01	2019-03-01
Timothy Maloney	2014-04-01	2017-05-01
Riad Sherif	2011-12-02	2014-04-01
Tom Rossi	2010-01-04	2011-02-02
David Meek	2007-07-13	2008-06-30

List of Public Offices Held
Position	Period Held	Last Date Designated Public Office Held
Special Assistant Health Canada, Minister's Office	January 1996 to June 1996	Not a designated office

Date Modified:: 2025-06-03

Search and menus

Language selection

Registration - In-house Corporation

Novartis Pharmaceuticals Canada Inc. / Mark Vineis, Country President

Registration Information

Associated Communications

Version 37 of 39 (2024-01-01 to 2024-05-01)

Version 37 of 39 (2024-01-01 to 2024-05-01)

Subject Matters

Subject Matter Details

Policies or Program

Policies or Program, Regulation

Regulation

Communication Techniques

Government Institutions

Description of activities

Responsible officer name and position during the period of this registration

Government funding

In-house Corporation Contact Information

Parent Company Information

Subsidiary Beneficiary Information

Senior Officers whose lobbying activities represent less than 20% of their Duties

Senior Officers and Employees whose lobbying activities represent 20% or more of their Duties